Literature DB >> 15458519

Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I.

Thierry Lavabre-Bertrand1, Jeanne Ramos, Christophe Delfour, Laurent Henry, Isabelle Guiraud, Serge Carillo, André Wagner, Jean Paul Bureau, Pierre Blanc.   

Abstract

Interferon has been shown to be an effective treatment of congenital dyserythropoiesis type I (CDA-I), but the optimal dose and the feasibility of this treatment remains to be determined. Here, in a 9-yr follow-up of a single patient, we show that interferon remains active during such a long period. The optimal dose of conventional alpha interferon could be evaluated at 2 million units twice a week. Pegylated interferon could be used as well at a dose of 30 microg/wk. During interferon treatment, serum and erythrocyte ferritin levels decreased progressively, and remained inversely correlated with haemoglobin levels. On repeated liver biopsies, iron overload could be normalized. Low dose interferon is a long-term treatment of CDA-I, and allows a significant decrease in iron overload, that could be interesting even in patients who are only moderately anaemic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458519     DOI: 10.1111/j.1600-0609.2004.00310.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Close to unraveling the secrets of congenital dyserythropoietic anemia types I and II.

Authors:  Achille Iolascon; Jean Delaunay
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation.

Authors:  Maurizio Miano; Dirk-Jan Eikema; Mahmoud Aljurf; Pieter J Van't Veer; Gülyüz Öztürk; Matthias Wölfl; Frans Smiers; Angsar Schulz; Gerard Socié; Kim Vettenranta; Cristina Diaz de Heredia; Marco Zecca; Johan Maertens; Montserrat Rovira; Jorge Sierra; Duygu Uckan-Cetinkaya; Elena Skorobogatova; Ali Bülent Antmen; Jean-Hugues Dalle; Miroslaw Markiewicz; Rose Marie Hamladji; Vassiliki Kitra-Roussou; Giorgio La Nasa; Gergely Kriván; Amal Al-Seiraihy; Stefano Giardino; Antonio Maria Risitano; Regis Peffault de Latour; Carlo Dufour
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

3.  Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha.

Authors:  Ayse Salihoglu; Tugrul Elverdi; Ahmet Emre Eskazan; Deniz Eyice; Isil Bavunoglu; Muhlis Cem Ar; Seniz Ongoren; Elif Guzel; Zafer Baslar; Aydin Tunckale; Nukhet Tuzuner; Teoman Soysal
Journal:  Indian J Hematol Blood Transfus       Date:  2015-09-21       Impact factor: 0.900

4.  Congenital dyserythropoietic anemia.

Authors:  Takahiro Kamiya; Atsushi Manabe
Journal:  Int J Hematol       Date:  2010-09-07       Impact factor: 2.490

Review 5.  The congenital dyserythropoieitic anemias: genetics and pathophysiology.

Authors:  Richard King; Patrick J Gallagher; Rami Khoriaty
Journal:  Curr Opin Hematol       Date:  2021-12-24       Impact factor: 3.218

6.  Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).

Authors:  Omar Niss; Robert B Lorsbach; Mikaela Berger; Satheesh Chonat; Morgan McLemore; David Buchbinder; Timothy McCavit; Linda G Shaffer; Jessica Simpson; Jeffrey H Schwartz; Jessica Meznarich; Myesa Emberesh; Katie G Seu; Wenying Zhang; Theodosia A Kalfa
Journal:  Blood Cells Mol Dis       Date:  2020-12-24       Impact factor: 3.039

Review 7.  The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.

Authors:  Noémi B A Roy; Christian Babbs
Journal:  Br J Haematol       Date:  2019-03-05       Impact factor: 6.998

Review 8.  Congenital dyserythropoietic anemias: molecular insights and diagnostic approach.

Authors:  Achille Iolascon; Hermann Heimpel; Anders Wahlin; Hannah Tamary
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.